GT199900132A - Inhibidores de tace. - Google Patents
Inhibidores de tace.Info
- Publication number
- GT199900132A GT199900132A GT199900132A GT199900132A GT199900132A GT 199900132 A GT199900132 A GT 199900132A GT 199900132 A GT199900132 A GT 199900132A GT 199900132 A GT199900132 A GT 199900132A GT 199900132 A GT199900132 A GT 199900132A
- Authority
- GT
- Guatemala
- Prior art keywords
- sup
- cancer
- treatment
- inhibitors
- combination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
Abstract
LA PRESENTE INVENCIÒN SE REFIERE A DERIVADOS DE HIDROXAMIDA (DE ACUERDO A LA ESTRUCTURA ESQUEMATIZADA, DONDE LAS LETRAS "R, X & Q"SE LISTAN ESPECÌFICAMENTE EN EL DOCUMENTO ORIGINAL)) Y A COMPOSICIONES FARMACÈUTICAS QUE COMPRENDEN TALES DERIVADOS Y AL USO DE TALES DERIVADOS EN EL TRATAMIENTO DE LA ARTRITIS, CÀNCER, ENFERMEDAD INFLAMATORIA DEL INTESTINO, ENFERMEDAD DE CROHN, ENDISEMA, SÌNDROME DE DIFICULTAD RESPIRATORIA AGUDA, ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRÒNICA, ENFERMEDAD DE ALZHEIMER, TOXICIDAD EN EL TRASPLANTE DE UN ÒRGANO, CAQUEXIA, REACCIONES ALÈRGICAS, HIPERSENSIBILIDAD POR CONTACTO ALÈRGICA, CÀNCER, ULCERACIÒN DE TEJIDOS, RESTENOSIS, ENFERMEDAD PERIODONTAL, EPIDERMÒLISIS AMPOLLOSA, OSTEOPORÒSIS, FALTA DE FIRMEZA EN IMPLANTES EN ARTICULACIONES ARTIFICIALES, ATEROSCLEROSIS, AEURISMA AÒRTICO, INSUFICIENCIA CARDÌACA CONFESTIVA, INFARTO DEMUOCARDIO, ACCIDENTES CEREBROVASCULARES, ISQUEMIA CEREBRAL, TRAUMATISMO CRANEAL, LESIÒN LA MÈDULA ESPINAL, TRASTORNOS DEGENERATIVOS, TRASTORNOS AUTOINMUNES, ENFERMEDAD DE HUNTINGTON, ENFERMEDAD PARKINSON, MIGRAÑA, DEPRESIÒN, NEUROPATÌA, PERIFÈRICA, DOLOR, ANGIPATÌA AMILOIDE CEREBRAL, POTENCIACIÒN NOOTRÒPICA O COGNOSCITIVA, ESCLEROSIS LATERAL AMIOTRÒFICA, ESCLEROSIS MÙLTIPLE, ANGIOGÈNESIS OCULAR, LESIÒN CORNEAL, DEGENERACIÒN MACULAR, CURACIÒN ANÒMALA DE HERIDAS, SIDA Y SEPTICEMIA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9625698P | 1998-08-12 | 1998-08-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT199900132A true GT199900132A (es) | 2001-02-02 |
Family
ID=22256553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT199900132A GT199900132A (es) | 1998-08-12 | 1999-08-12 | Inhibidores de tace. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20030181441A1 (es) |
EP (1) | EP1104412B1 (es) |
JP (1) | JP3623448B2 (es) |
AT (1) | ATE297908T1 (es) |
AU (1) | AU4925099A (es) |
BR (1) | BR9912944A (es) |
CA (1) | CA2340182A1 (es) |
DE (1) | DE69925840T2 (es) |
ES (1) | ES2242402T3 (es) |
GT (1) | GT199900132A (es) |
MA (1) | MA26674A1 (es) |
PA (1) | PA8479901A1 (es) |
TN (1) | TNSN99157A1 (es) |
UY (1) | UY25992A1 (es) |
WO (1) | WO2000009492A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6406901B1 (en) | 1995-06-08 | 2002-06-18 | Immunex Corporation | TNF-a converting enzyme |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
EP1081137A1 (en) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
GB9922825D0 (en) * | 1999-09-25 | 1999-11-24 | Smithkline Beecham Biolog | Medical use |
GB0004531D0 (en) * | 2000-02-25 | 2000-04-19 | Richards Andrew J M | The treatment of respiratory diseases |
US6458822B2 (en) | 2000-03-13 | 2002-10-01 | Pfizer Inc. | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases |
EP1138680A1 (en) * | 2000-03-29 | 2001-10-04 | Pfizer Products Inc. | Gem substituted sulfonyl hydroxamic acids as MMP inhibitors |
MXPA01013326A (es) | 2001-02-14 | 2002-08-26 | Warner Lambert Co | Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz. |
US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
AUPR726201A0 (en) * | 2001-08-24 | 2001-09-20 | Fujisawa Pharmaceutical Co., Ltd. | New use of a cyclic compound |
ES2425013T3 (es) | 2002-06-12 | 2013-10-10 | Symphony Evolution, Inc. | Inhibidores de ADAM-10 humana |
WO2005021489A2 (en) | 2002-12-23 | 2005-03-10 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
JP2006522824A (ja) * | 2003-04-09 | 2006-10-05 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症性疾患を処置するために有用なβ−カルボリン |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
KR20070014166A (ko) | 2004-04-09 | 2007-01-31 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 염증 질환 치료에 유용한 베타-카르볼린 |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
WO2007016597A2 (en) * | 2005-07-29 | 2007-02-08 | The Regents Of The University Of California | Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy |
DK2041181T3 (da) * | 2006-06-08 | 2011-08-29 | Helmholtz Zentrum Muenchen | Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
IT1404729B1 (it) * | 2011-01-27 | 2013-11-29 | Univ Pisa | Inibitori altamente selettivi dell'attivita' di adams |
JP2014528963A (ja) * | 2011-10-04 | 2014-10-30 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル)Inserm(Institut National Dela Sante Etde La Recherche Medicale) | 新規のアポトーシス誘導化合物 |
CN111500721B (zh) * | 2020-04-20 | 2022-11-29 | 青岛大学附属医院 | Tace在腹主动脉瘤腔内修复术后内漏诊断中的应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT874830E (pt) * | 1995-12-08 | 2003-06-30 | Agouron Pharma | Inibidor de metaloproteinases composicao farmaceutica contendo este inibidor e a utilizacao farmaceutica e metodo util para a sua preparacao |
US5753653A (en) * | 1995-12-08 | 1998-05-19 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
EP0925287B1 (en) * | 1996-08-28 | 2003-01-15 | The Procter & Gamble Company | Heterocyclic metalloprotease inhibitors |
KR20000057595A (ko) * | 1996-12-17 | 2000-09-25 | 후지야마 아키라 | Mmp 또는 tnf의 억제제로서 피페라진 화합물 |
TR199901926T2 (xx) * | 1997-02-11 | 1999-12-21 | Pfizer Inc. | Arils�lfonil hidroksamik asit t�revleri |
EP1081137A1 (en) * | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
-
1999
- 1999-08-05 AU AU49250/99A patent/AU4925099A/en not_active Abandoned
- 1999-08-05 ES ES99933079T patent/ES2242402T3/es not_active Expired - Lifetime
- 1999-08-05 EP EP99933079A patent/EP1104412B1/en not_active Expired - Lifetime
- 1999-08-05 WO PCT/IB1999/001392 patent/WO2000009492A1/en active IP Right Grant
- 1999-08-05 BR BR9912944-2A patent/BR9912944A/pt not_active IP Right Cessation
- 1999-08-05 CA CA002340182A patent/CA2340182A1/en not_active Abandoned
- 1999-08-05 DE DE69925840T patent/DE69925840T2/de not_active Expired - Fee Related
- 1999-08-05 JP JP2000564944A patent/JP3623448B2/ja not_active Expired - Fee Related
- 1999-08-05 AT AT99933079T patent/ATE297908T1/de not_active IP Right Cessation
- 1999-08-06 PA PA19998479901A patent/PA8479901A1/es unknown
- 1999-08-11 MA MA25729A patent/MA26674A1/fr unknown
- 1999-08-11 TN TNTNSN99157A patent/TNSN99157A1/fr unknown
- 1999-08-12 GT GT199900132A patent/GT199900132A/es unknown
- 1999-08-12 US US09/373,182 patent/US20030181441A1/en not_active Abandoned
-
2000
- 2000-01-28 UY UY25992A patent/UY25992A1/es not_active Application Discontinuation
-
2005
- 2005-05-03 US US11/120,846 patent/US20050215549A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE297908T1 (de) | 2005-07-15 |
UY25992A1 (es) | 2000-03-31 |
TNSN99157A1 (fr) | 2005-11-10 |
AU4925099A (en) | 2000-03-06 |
EP1104412B1 (en) | 2005-06-15 |
JP2003526604A (ja) | 2003-09-09 |
CA2340182A1 (en) | 2000-02-24 |
DE69925840T2 (de) | 2006-05-04 |
EP1104412A1 (en) | 2001-06-06 |
US20050215549A1 (en) | 2005-09-29 |
US20030181441A1 (en) | 2003-09-25 |
WO2000009492A1 (en) | 2000-02-24 |
MA26674A1 (fr) | 2004-12-20 |
JP3623448B2 (ja) | 2005-02-23 |
DE69925840D1 (de) | 2005-07-21 |
BR9912944A (pt) | 2001-05-08 |
ES2242402T3 (es) | 2005-11-01 |
PA8479901A1 (es) | 2000-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8479901A1 (es) | Inhibidores de tace | |
CA2340202A1 (en) | Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors | |
CA2342271A1 (en) | Gem substituted hydroxamic acids | |
MY121754A (en) | Arylsulfonylamino hydroxamic acid derivatives | |
YU37499A (sh) | Derivati arilsulfonil hidroksamske kiseline | |
AP9801174A0 (en) | Cyclic sulfone derivatives. | |
TR200002951T2 (tr) | (4-Arilsülfonilamino)-tetrahidropiran-4-karboksilik asit hidroksamitler | |
BR0011539A (pt) | Hidroxamidas de ácido 3-(arilsulfonilamino)-tetrahidropirano-3-carboxìlico | |
ATE251618T1 (de) | 3-(arylsulfonylamino)-tetrahydrofuran-3- carbonsäure-hydroxamide | |
ECSP993099A (es) | Inhibidores de tace |